The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
iwCLL 2017 | What does epigenetics mean to CLL?
Christopher Oakes, PhD from Ohio State University, Columbus, OH highlights the importance of epigenetics in chronic lymphocytic leukemia (CLL) at the International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2017 in New York, NY. Dr Oakes reports on the diverse patterns of methylation in CLL which corresponds to outcome in patients. Epigenetics will not only have a role in disease regulation but more excitingly in predicting which patients will respond to certain therapies and in the production of biomarkers.
